Yes pretty much any IPO that goes down in price gets those "lawsuits" from lawyers looking to make money off the shareholders. Has had zero impact on price of stock from my experience.
All of my posts are just my opinion don't buy or sell a stock based on my opinion do your own research before investing.
Recent KALV News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:30:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:42:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:41:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:40:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:40:18 PM
- KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 11:00:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:01:00 PM
- KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference • Business Wire • 03/30/2026 11:00:00 AM
- Form 10-KT - Transition reports [Rule 13a-10 or 15d-10] • Edgar (US Regulatory) • 03/25/2026 08:35:23 PM
- KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period • IH Market News • 03/25/2026 12:39:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 11:16:51 AM
- KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update • Business Wire • 03/25/2026 11:00:00 AM
- KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference • Business Wire • 03/20/2026 11:00:00 AM
- KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 • Business Wire • 03/18/2026 11:00:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/04/2026 12:00:00 PM
- KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) • Business Wire • 03/02/2026 12:00:00 PM
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences • Business Wire • 02/25/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:44:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:44:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:43:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:42:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:42:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 12:45:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 12:44:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 12:44:07 AM
